Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -0.83%85 Return-on-Tangible-Asset is 4.67% as of Mar. 2026, which is 2% above its 10-year median of 4.56. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.51 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, ACME Laboratories ranks better than 51.69% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ACME Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was BDT2,792 Mil. ACME Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was BDT59,747 Mil. Therefore, ACME Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 4.67%.
The historical rank and industry rank for ACME Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
DHA:ACMELAB'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.36 Med: 4.56 Max: 5.06
Current: 3.36
During the past 9 years, ACME Laboratories's highest Return-on-Tangible-Asset was 5.06%. The lowest was 3.36%. And the median was 4.56%.
DHA:ACMELAB's Return-on-Tangible-Asset is ranked better than 51.69% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs DHA:ACMELAB: 3.36
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ACME Laboratories Return-on-Tangible-Asset Related Terms
ACME Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.67% mean?
ACME Laboratories (DHA:ACMELAB) has a Return-on-Tangible-Asset of 4.67% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ACME Laboratories and its competitors. This is near median its historical median of 4.56. Over the past decade, ACME Laboratories' Return-on-Tangible-Asset has ranged from 3.36 to 5.06. According to the industry distribution chart, ACME Laboratories ranks #487 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 48.3%.
Is ACME Laboratories' Return-on-Tangible-Asset too high?
ACME Laboratories' current Return-on-Tangible-Asset of 4.67% is near median its 10-year median of 4.56. Over the past 10 years, this metric has ranged from a low of 3.36 to a high of 5.06. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. ACME Laboratories' value of 4.67% is 49.7% above this industry median. Based on the distribution chart, ACME Laboratories ranks #487 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #487 out of 1008 companies for Return-on-Tangible-Asset. This puts ACME Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.12. ACME Laboratories' value of 4.67% is 49.7% above this benchmark. Historically, ACME Laboratories' own Return-on-Tangible-Asset has ranged from 3.36 to 5.06 over the past decade. While the company's 10-year median is 4.56 vs. the industry median of 3.12, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Return-on-Tangible-Asset of 4.67% is 49.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Return-on-Tangible-Asset is 4.67%, which is near median its own 10-year median of 4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.51, compared to a current price of BDT83.20 — trading 34.2% below its estimated fair value. The current Return-on-Tangible-Asset is 4.67%, which is near median its 10-year median of 4.56 and 49.7% above the Drug Manufacturers industry median of 3.12. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Return-on-Tangible-Asset is 4.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT83.20 is trading 34.2% below its estimated GF Value™ of BDT126.51.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Return-on-Tangible-Asset: 4.67% (near median its 10-year median of 4.56)
GF Value™: BDT126.51 vs. price of BDT83.20 (34.2% below fair value)
Industry Position: 49.7% above the Drug Manufacturers median (#487 of 1008)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
